Glycomimetic Selectin Inhibitors for Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, T-cell migration-related conditions, and selectin-associated cancers lack effective inhibitors, leading to chronic and potentially fatal complications with no cure available.
Innovation Solution
Development of specific glycomimetic compounds that act as inhibitors of selectins, which can be administered alone or combined with pharmaceutically acceptable carriers to treat diseases such as sickle cell disease, T-cell migration disorders, and selectin-related cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for sickle cell disease are used, then patients can manage symptoms, but life expectancy is shortened and no cure is available
Solution Approach 1:
The patent modifies the chemical structure of selectin inhibitors by changing parameters such as the sugar moiety, linker length, and aromatic group substitutions to optimize pharmacokinetic properties including half-life and binding affinity, thereby improving treatment effectiveness and potentially extending life expectancy
Solution Approach 2:
The invention creates composite molecular structures combining specific sugar units (e.g., sialic acid, galactose), linker groups (e.g., PEG chains), and aromatic moieties to design selectin inhibitors with enhanced and balanced pharmacokinetic properties that address both efficacy and duration concerns
2Reliability
If selectin inhibitors are developed to treat sickle cell disease, then complications may be reduced, but the complexity of the compound structure increases
Solution Approach 1:
The selectin inhibitor is divided into distinct functional segments: a sugar moiety for selectin binding, a linker group for flexibility and solubility, and an aromatic group for enhanced binding affinity. This segmentation allows each component to be optimized independently while maintaining overall efficacy
Solution Approach 2:
The patent uses linker groups (such as PEG chains) as intermediary elements connecting the sugar binding moiety to the aromatic group, providing flexibility and solubility while allowing the two functional ends to operate independently in binding to the selectin target
3Reliability
If glycomimetic compounds are used as selectin inhibitors, then pharmacokinetic activity may be enhanced, but the difficulty of manufacturing increases
Solution Approach 1:
The patent employs protected sugar intermediates and pre-formed linker-aromatic conjugates in the synthesis pathway, allowing key functional groups to be installed early in the sequence under optimized conditions, thereby simplifying later steps and improving overall manufacturing efficiency
Solution Approach 2:
The invention modifies synthesis parameters such as protecting group selection, solvent systems, and coupling reagents to optimize the manufacturing process for glycomimetic compounds, balancing pharmacokinetic enhancement with practical synthesizability
Data Source
AI summary
Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.